long-term survival

$Five-Year Survival and Durable Remission with Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Insights from the TRANSCEND NHL 001 Study$

Five-Year Survival and Durable Remission with Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Insights from the TRANSCEND NHL 001 Study

By MedXY 09/18/2026

Lisocabtagene maraleucel demonstrates durable five-year survival and potential cure in relapsed/refractory large B-cell lymphoma, with manageable long-term safety, based on data from the TRANSCEND NHL 001 trial and its long-term follow-up.

General Surgery news Oncology

Impact of Severe Anastomotic Leak After Esophagectomy on Long-Term Survival: Insights from a Modern Multicenter Cohort

By MedXY 09/11/2026

A large European study shows that severe anastomotic leaks requiring surgical reintervention after esophagectomy significantly reduce long-term survival and increase postoperative mortality, underscoring the need for targeted management strategies.

Cardiology General Surgery news

Sex and Age Influence Outcomes After Ruptured Abdominal Aortic Aneurysm Repair: Insights from a Dutch Nationwide Cohort

By MedXY 08/16/2026

This nationwide Dutch cohort study reveals sex- and age-specific differences in mortality, long-term survival, and postdischarge care after ruptured abdominal aortic aneurysm repair, emphasizing the need for tailored management in women.

General Surgery news Oncology

Long-Term Survival and Curative Potential of Liver Transplantation for Nonresectable Colorectal Liver Metastases: Insights from the SECA-II Study

By MedXY 08/14/2026

A decade-long follow-up of the SECA-II study demonstrates that liver transplantation in highly selected patients with nonresectable colorectal liver-only metastases yields substantial long-term survival and may offer curative potential even after relapse.

Cardiology news

Long-Term Survival Outcomes in Asymptomatic Patients with Degenerative Mitral Regurgitation: Insights from a 25-Year Prospective Cohort Study

By MedXY 08/03/2026

This 25-year prospective study evaluates the prognostic value of quantified mitral regurgitation (MR) severity and shows that early surgical intervention in upper-moderate MR improves long-term survival in asymptomatic patients.

Clinical Updates news Oncology

Long-Term Survival Following Cytoreductive Surgery and HIPEC for Pseudomyxoma Peritonei: Insights from a 22-Year Single Institution Experience and Contemporary Evidence Synthesis

By MedXY 11/06/2025

22-year single-center data confirm CRS and HIPEC as safe, effective for PMP, yielding 62% 5-year survival. Prognostic factors, optimized HIPEC regimens, and perioperative management impact outcomes and recurrence.

Cardiology news

Long-Term Survival Outcomes After Initial Stress Testing Versus Coronary CTA in Suspected CAD: Insights from the PROMISE Trial

By MedXY 09/27/2025

The PROMISE trial's 10-year follow-up shows no difference in all-cause or cardiovascular mortality between initial functional stress testing and anatomic coronary CTA in symptomatic patients with suspected coronary artery disease.

Clinical Updates news

Advancements in Long-Term Outcomes for Multiple Myeloma: Insights from Early Total Therapy Protocols

By MedXY 08/23/2025

A secondary analysis of three total therapy clinical trials reveals significant long-term survival improvements in multiple myeloma patients with modern combinational and stem cell transplant approaches incorporating immunomodulatory and proteasome inhibitors.

$Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients$

Clinical Updates Hematology-Oncology Medical News Specialties

Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients

By MedXY 08/01/2025

A recent J Clin Oncol study shows that nearly 33% of RRMM patients treated with cilta-cel achieved ≥5 years of progression-free survival, highlighting durable responses and promising biomarkers.